Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
September S&P 500 futures (ESU23) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.22% this morning as market participants looked ahead to the release of the Fed’s favorite...
The trio all have late-stage therapies with blockbuster potential.
The company released positive results for its lead therapy.
89bio, Inc. (NASDAQ: ETNB) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of
- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial...
SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...
SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...